Skip to main content
OpenTrials
Completed

NCT Number: NCT02752165

Telemedicine Enhanced Asthma Management Through the Emergency Department

In the US, children from minority ethnic and racial backgrounds suffer disproportionately from asthma and account for substantially more emergency department (ED) visits and hospitalizations than non-minority children. While NHLBI guidelines recommend daily preventive medications for all children with persistent asthma to prevent morbidity as well as ED visits and hospitalizations, many children who should receive preventive medications are not receiving them. This is in part because children presenting to the ED for an acute asthma exacerbation rarely receive preventive asthma care, due to the ED's focus on acute, episodic care. The NHLBI guidelines recommend that children follow-up with a primary care provider (PCP) within 1-4 weeks of the ED visit. The post-ED follow-up visit is an opportunity for the PCP to prescribe effective preventive asthma medications, step-up medication for children who demonstrate poor control, promote adherence, and provide education on asthma self-management and trigger control. However, rates for follow-up after an asthma-related ED visit are extremely low, and preventive care is delivered inconsistently even when children are seen in follow-up. In the investigators' prior work they have found that a provider prompting intervention can enhance the delivery of guideline-based preventive asthma treatments at the time of a primary care office visit and ultimately reduce morbidity. They have also found that telemedicine can link children with persistent asthma to a provider for optimal chronic illness management. The goal of this project is to use a novel telemedicine-based program to facilitate primary care follow-up and promote the delivery of guideline-based preventive care for high-risk children presenting to the ED for an asthma exacerbation. The investigators will utilize a 2-group randomized trial to test the TEAM-ED intervention. The intervention includes: 1) a telemedicine assessment at the child's school within one week of discharge from the ED and completed by a PCP, 2) 'point-of-care' prompting to promote the provision of guideline-based preventive care during the telemedicine visit, and 3) two additional telemedicine-assisted follow-up assessments to assure optimal response to treatment and tailor the care regimen as needed. The investigators will assess the effectiveness of the program in reducing respiratory morbidity and improving preventive asthma care, with follow-up assessments at 3, 6, 9, and 12 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Rochester

Rochester, New York, 14642, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Prior physician diagnosis of asthma
  • current emergency visit for an acute asthma exacerbation, requiring nebulized albuterol therapy
  • Persistent or poor control of asthma, defined by NHLBI guidelines

Exclusion criteria

  • Inability to speak and understand either English or Spanish
  • No access to a phone for follow-up surveys
  • Participation in another asthma study at the time of enrollment, or a sibling participating in this or another study Other significant medical conditions that could interfere with assessment of asthma-related measures
  • children in foster care or other situations in which consent cannot be obtained from a legal guardian

Treatment and study plan

TEAM-ED

Other

Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting

Enhanced usual care

Other

Report of symptoms to primary care physician

Primary outcomes

  1. Number of Symptom-Free Days in the Prior 2 Weeks

    Time frame: At the 3-month follow-up assessment

    Number of days without symptoms in the prior 2 weeks

  2. Number of Symptom-Free Days in the Prior 2 Weeks

    Time frame: At the 6-month follow-up assessment

    Number of days without symptoms in the prior 2 weeks

  3. Number of Symptom-Free Days in the Prior 2 Weeks

    Time frame: At the 9-month follow-up assessment

    Number of days without symptoms in the prior 2 weeks

  4. Number of Symptom-Free Days in the Prior 2 Weeks

    Time frame: At the 12-month follow-up assessment

    Number of days without symptoms in the prior 2 weeks

Sponsors and collaborators

Lead sponsor

University of Rochester

Other

Registry information

Acronym: TEAM-ED

Important dates

Study start
2016
Primary completion
2022
Study completion
2022
First posted
Apr 26, 2016
Registry last updated
Sep 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.